Anirban Adhikary1*, Kakoli Halder1, Debmalya Ghosh1, Snehansu Biswas2, Indranil Chatterjee2 and Suman Kumar Nath2
1B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India
2Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India
*Corresponding Author: Anirban Adhikary, B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India.
Received: August 24, 2020; Published: October 15, 2020
The pandemic flare-up of coronavirus disease 2019 (COVID-19) is quickly spreading everywhere throughout the world. Reports from China indicated that about 20% of patients created severe disease, bringing about a casualty of 4%. In the previous two months, we clinical immunologists took an interest in multi-rounds of MDT (multidiscipline group) conversation on the counter aggravation the executives of basic COVID-19 patients, with our partners dispatched from Chinese driving PUMC Hospital to Wuhan to concede and treat the most serious patients. Here, from the point of view of clinical immunologists, we will examine the clinical and immunological attributes of severe patients, and sum up the current proof and offer our involvement with hostile to anti-inflammation treatment, including glucocorticoids, IL-6 adversary, JAK inhibitors and chloroquine/hydroxychloroquine, of patients with extreme COVID-19 that may have an impeded safe framework.
Keywords: Coronavirus Disease 2019 (COVID-19); Cytokine Storm; Anti-inflammation Treatment
Citation: Anirban Adhikary., et al. “A Review of Anti-Inflammatory Drugs Use in the Treatment of People Infected by Coronavirus Disease 2019 (COVID-19)". Acta Scientific Microbiology 3.11 (2020): 28-34.
Copyright: © 2020 Anirban Adhikary., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.